



Paris, 31th March 2022

Object: Invitation to participate in a clinical study of masitinib for the treatment of amyotrophic lateral sclerosis (ALS)

Dear Madam, Dear Sir,

AB Science, a French biotech company, has launched a new international clinical trial (AB19001) with its lead oral compound masitinib for the treatment of amyotrophic lateral sclerosis (ALS), and in particular in Spain. We are pleased to invite all patients of your association to contact their doctors should they wish to participate to this study.

Centers opened or that will be opened in Spain include:

- Hospital Carlos III
C/ Sinesio Delgado 10 28029 MADRID
Principal Investigator: Dr Javier Mascías Cadavid
jmascias@yahoo.es
- ALS Unit Hospital San Rafael
Serrano 199. 28016 Madrid
Principal Investigator: Dr Jesus Mora
jesussmora@icloud.com
- Hospital Universitari de Bellvitge
Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat (Barcelona)
Principal Investigator: Dr Andres Paipa
andres.paipa@bellvitgehospital.cat
- Hospital Universitario y Politécnico La Fe
Avda Fernando Abril Martorell 106-Torre D, 5 46026, Valencia
Principal Investigator: Dr Juan F Vázquez-Costa
vazquez_juacos@gva.es
- Clinical Hospital Santiago de Compostela
Travesía Choupana, s/n 15706 Santiago de Compostela (A Coruña)
Principal Investigator: Dr Julio Pardo
julio.pardo.fernandez@sergas.es

AB Science has already conducted one clinical trial with masitinib in ALS patients (study AB10015). The results obtained from this study showed that oral masitinib (4.5 mg/kg/d) administered as an add-on to riluzole was most effective in patients having less rapidly progressing disease, i.e., an ALS Functional Rating Scale-revised (ALSFRS-R) progression rate of less than 1.1 points per month. These findings have been published in the medical journal *Amyotrophic Lateral Sclerosis and*

Frontotemporal Degeneration (Jesus S. Mora., et al, 2019), a copy of which can be freely accessed online (<https://pubmed.ncbi.nlm.nih.gov/31280619/>) and has also been attached here for your convenience.

In addition, a long-term survival analysis (75 months average follow-up from diagnosis) of all patients originally randomized in study AB10015 has been performed with findings published in the journal *Therapeutic Advances in Neurological Disorders* (Jesus S. Mora., et al, 2021). Results of that analysis indicated that masitinib (4.5 mg/kg/d) showed greatest benefit when treatment was started as early as possible, prior to severe impairment of functionality. This publication can again be freely accessed via the journal website (<https://pubmed.ncbi.nlm.nih.gov/34457038/>) and is included as an attachment.

The new confirmatory clinical trial (study AB19001) primarily recruits ALS patients with an ALSFRS-R progression rate of between 0.3 and 1.1 points per month and who have mild or moderate (non severe) impairment of functionality (i.e., a functional score at least 2 on each of ALSFRS-R items at baseline).

Your interest in study AB19001 and support by sharing this invitation to participate with the members of your association is very much appreciated. The objective is to obtain results as soon as possible, which if positive may then support the registration of a new drug to patient with ALS.

We remain at your disposal should you have any questions.

Alain Moussy
CEO AB Science

